nodes	percent_of_prediction	percent_of_DWPC	metapath
Enzalutamide—CYP2C8—Mometasone—systemic scleroderma	0.124	0.158	CbGbCtD
Enzalutamide—ALB—Captopril—systemic scleroderma	0.0813	0.104	CbGbCtD
Enzalutamide—ALB—Mycophenolate mofetil—systemic scleroderma	0.064	0.0815	CbGbCtD
Enzalutamide—ABCB1—Lisinopril—systemic scleroderma	0.0568	0.0723	CbGbCtD
Enzalutamide—CYP2C9—Leflunomide—systemic scleroderma	0.0559	0.0711	CbGbCtD
Enzalutamide—CYP3A5—Mycophenolate mofetil—systemic scleroderma	0.0515	0.0655	CbGbCtD
Enzalutamide—ALB—Prednisone—systemic scleroderma	0.0512	0.0651	CbGbCtD
Enzalutamide—CYP2C8—Mycophenolate mofetil—systemic scleroderma	0.0495	0.063	CbGbCtD
Enzalutamide—ABCB1—Captopril—systemic scleroderma	0.0426	0.0541	CbGbCtD
Enzalutamide—CYP2D6—Captopril—systemic scleroderma	0.0401	0.051	CbGbCtD
Enzalutamide—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0335	0.0426	CbGbCtD
Enzalutamide—CYP2C19—Prednisone—systemic scleroderma	0.0332	0.0422	CbGbCtD
Enzalutamide—ABCB1—Prednisone—systemic scleroderma	0.0268	0.0341	CbGbCtD
Enzalutamide—ALB—Methotrexate—systemic scleroderma	0.0257	0.0327	CbGbCtD
Enzalutamide—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0201	0.0255	CbGbCtD
Enzalutamide—CYP3A4—Prednisone—systemic scleroderma	0.016	0.0204	CbGbCtD
Enzalutamide—ABCB1—Methotrexate—systemic scleroderma	0.0134	0.0171	CbGbCtD
Enzalutamide—CYP2C9—cardial valve—systemic scleroderma	0.00512	0.529	CbGeAlD
Enzalutamide—Infection—Pentoxifylline—systemic scleroderma	0.000899	0.0044	CcSEcCtD
Enzalutamide—Pneumonia—Leflunomide—systemic scleroderma	0.000891	0.00436	CcSEcCtD
Enzalutamide—Neutropenia—Mycophenolic acid—systemic scleroderma	0.000887	0.00434	CcSEcCtD
Enzalutamide—Infestation NOS—Leflunomide—systemic scleroderma	0.000886	0.00434	CcSEcCtD
Enzalutamide—Infestation—Leflunomide—systemic scleroderma	0.000886	0.00434	CcSEcCtD
Enzalutamide—Thrombocytopenia—Pentoxifylline—systemic scleroderma	0.000886	0.00434	CcSEcCtD
Enzalutamide—Nasopharyngitis—Lisinopril—systemic scleroderma	0.000884	0.00432	CcSEcCtD
Enzalutamide—Upper respiratory tract infection—Mycophenolic acid—systemic scleroderma	0.000881	0.00431	CcSEcCtD
Enzalutamide—Skin disorder—Pentoxifylline—systemic scleroderma	0.000879	0.0043	CcSEcCtD
Enzalutamide—Pollakiuria—Mycophenolic acid—systemic scleroderma	0.000876	0.00429	CcSEcCtD
Enzalutamide—Pneumonia—Mycophenolic acid—systemic scleroderma	0.00085	0.00416	CcSEcCtD
Enzalutamide—Infestation—Mycophenolic acid—systemic scleroderma	0.000846	0.00414	CcSEcCtD
Enzalutamide—Infestation NOS—Mycophenolic acid—systemic scleroderma	0.000846	0.00414	CcSEcCtD
Enzalutamide—Haematuria—Leflunomide—systemic scleroderma	0.000845	0.00414	CcSEcCtD
Enzalutamide—Epistaxis—Leflunomide—systemic scleroderma	0.000836	0.00409	CcSEcCtD
Enzalutamide—Sinusitis—Leflunomide—systemic scleroderma	0.000832	0.00407	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Pentoxifylline—systemic scleroderma	0.000825	0.00403	CcSEcCtD
Enzalutamide—Bronchitis—Lisinopril—systemic scleroderma	0.000821	0.00402	CcSEcCtD
Enzalutamide—Insomnia—Pentoxifylline—systemic scleroderma	0.000819	0.00401	CcSEcCtD
Enzalutamide—Arthralgia—Mometasone—systemic scleroderma	0.000815	0.00399	CcSEcCtD
Enzalutamide—Haematuria—Mycophenolic acid—systemic scleroderma	0.000806	0.00395	CcSEcCtD
Enzalutamide—Neutropenia—Lisinopril—systemic scleroderma	0.000799	0.00391	CcSEcCtD
Enzalutamide—Rhinitis—Leflunomide—systemic scleroderma	0.000798	0.0039	CcSEcCtD
Enzalutamide—Epistaxis—Mycophenolic acid—systemic scleroderma	0.000798	0.0039	CcSEcCtD
Enzalutamide—Upper respiratory tract infection—Lisinopril—systemic scleroderma	0.000794	0.00388	CcSEcCtD
Enzalutamide—Sinusitis—Mycophenolic acid—systemic scleroderma	0.000793	0.00388	CcSEcCtD
Enzalutamide—Pharyngitis—Leflunomide—systemic scleroderma	0.00079	0.00386	CcSEcCtD
Enzalutamide—Urinary tract disorder—Leflunomide—systemic scleroderma	0.000786	0.00385	CcSEcCtD
Enzalutamide—Oedema peripheral—Leflunomide—systemic scleroderma	0.000784	0.00384	CcSEcCtD
Enzalutamide—Connective tissue disorder—Leflunomide—systemic scleroderma	0.000782	0.00383	CcSEcCtD
Enzalutamide—Urethral disorder—Leflunomide—systemic scleroderma	0.00078	0.00382	CcSEcCtD
Enzalutamide—Infection—Mometasone—systemic scleroderma	0.000776	0.0038	CcSEcCtD
Enzalutamide—Pneumonia—Lisinopril—systemic scleroderma	0.000766	0.00375	CcSEcCtD
Enzalutamide—Muscular weakness—Mycophenolate mofetil—systemic scleroderma	0.000764	0.00374	CcSEcCtD
Enzalutamide—Rhinitis—Mycophenolic acid—systemic scleroderma	0.000761	0.00372	CcSEcCtD
Enzalutamide—Hypoaesthesia—Mycophenolic acid—systemic scleroderma	0.000755	0.0037	CcSEcCtD
Enzalutamide—Pharyngitis—Mycophenolic acid—systemic scleroderma	0.000753	0.00369	CcSEcCtD
Enzalutamide—Musculoskeletal stiffness—Methotrexate—systemic scleroderma	0.000753	0.00369	CcSEcCtD
Enzalutamide—Urinary tract disorder—Mycophenolic acid—systemic scleroderma	0.00075	0.00367	CcSEcCtD
Enzalutamide—Oedema peripheral—Mycophenolic acid—systemic scleroderma	0.000748	0.00366	CcSEcCtD
Enzalutamide—Connective tissue disorder—Mycophenolic acid—systemic scleroderma	0.000746	0.00365	CcSEcCtD
Enzalutamide—Urethral disorder—Mycophenolic acid—systemic scleroderma	0.000744	0.00364	CcSEcCtD
Enzalutamide—Haematuria—Lisinopril—systemic scleroderma	0.000726	0.00355	CcSEcCtD
Enzalutamide—Bronchitis—Mycophenolate mofetil—systemic scleroderma	0.00072	0.00352	CcSEcCtD
Enzalutamide—Epistaxis—Lisinopril—systemic scleroderma	0.000718	0.00352	CcSEcCtD
Enzalutamide—Arthralgia—Captopril—systemic scleroderma	0.000715	0.0035	CcSEcCtD
Enzalutamide—Sinusitis—Lisinopril—systemic scleroderma	0.000715	0.0035	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Mometasone—systemic scleroderma	0.000711	0.00348	CcSEcCtD
Enzalutamide—Sepsis—Prednisone—systemic scleroderma	0.000702	0.00343	CcSEcCtD
Enzalutamide—Paraesthesia—Mometasone—systemic scleroderma	0.000701	0.00343	CcSEcCtD
Enzalutamide—Neutropenia—Mycophenolate mofetil—systemic scleroderma	0.0007	0.00342	CcSEcCtD
Enzalutamide—Mental disorder—Leflunomide—systemic scleroderma	0.000697	0.00341	CcSEcCtD
Enzalutamide—Pollakiuria—Mycophenolate mofetil—systemic scleroderma	0.000691	0.00338	CcSEcCtD
Enzalutamide—Angiopathy—Mycophenolic acid—systemic scleroderma	0.000689	0.00337	CcSEcCtD
Enzalutamide—Rhinitis—Lisinopril—systemic scleroderma	0.000685	0.00335	CcSEcCtD
Enzalutamide—Pharyngitis—Lisinopril—systemic scleroderma	0.000679	0.00332	CcSEcCtD
Enzalutamide—Urinary tract disorder—Lisinopril—systemic scleroderma	0.000675	0.0033	CcSEcCtD
Enzalutamide—Oedema peripheral—Lisinopril—systemic scleroderma	0.000674	0.0033	CcSEcCtD
Enzalutamide—Fatigue—Mometasone—systemic scleroderma	0.000673	0.00329	CcSEcCtD
Enzalutamide—Thrombocytopenia—Captopril—systemic scleroderma	0.000672	0.00329	CcSEcCtD
Enzalutamide—Pneumonia—Mycophenolate mofetil—systemic scleroderma	0.000671	0.00328	CcSEcCtD
Enzalutamide—Urethral disorder—Lisinopril—systemic scleroderma	0.00067	0.00328	CcSEcCtD
Enzalutamide—Back pain—Leflunomide—systemic scleroderma	0.00067	0.00328	CcSEcCtD
Enzalutamide—Infestation NOS—Mycophenolate mofetil—systemic scleroderma	0.000667	0.00327	CcSEcCtD
Enzalutamide—Infestation—Mycophenolate mofetil—systemic scleroderma	0.000667	0.00327	CcSEcCtD
Enzalutamide—Mental disorder—Mycophenolic acid—systemic scleroderma	0.000665	0.00325	CcSEcCtD
Enzalutamide—Leukopenia—Azathioprine—systemic scleroderma	0.000657	0.00321	CcSEcCtD
Enzalutamide—Asthenia—Pentoxifylline—systemic scleroderma	0.000649	0.00318	CcSEcCtD
Enzalutamide—Pruritus—Pentoxifylline—systemic scleroderma	0.00064	0.00313	CcSEcCtD
Enzalutamide—Back pain—Mycophenolic acid—systemic scleroderma	0.000639	0.00313	CcSEcCtD
Enzalutamide—Injury—Prednisone—systemic scleroderma	0.000639	0.00312	CcSEcCtD
Enzalutamide—Haematuria—Mycophenolate mofetil—systemic scleroderma	0.000636	0.00311	CcSEcCtD
Enzalutamide—Epistaxis—Mycophenolate mofetil—systemic scleroderma	0.000629	0.00308	CcSEcCtD
Enzalutamide—Sinusitis—Mycophenolate mofetil—systemic scleroderma	0.000626	0.00306	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Captopril—systemic scleroderma	0.000625	0.00306	CcSEcCtD
Enzalutamide—Amnesia—Prednisone—systemic scleroderma	0.000625	0.00306	CcSEcCtD
Enzalutamide—Arthralgia—Azathioprine—systemic scleroderma	0.000624	0.00306	CcSEcCtD
Enzalutamide—Vertigo—Leflunomide—systemic scleroderma	0.000622	0.00305	CcSEcCtD
Enzalutamide—Insomnia—Captopril—systemic scleroderma	0.00062	0.00304	CcSEcCtD
Enzalutamide—Angiopathy—Lisinopril—systemic scleroderma	0.00062	0.00304	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—systemic scleroderma	0.00062	0.00303	CcSEcCtD
Enzalutamide—Leukopenia—Leflunomide—systemic scleroderma	0.00062	0.00303	CcSEcCtD
Enzalutamide—Diarrhoea—Pentoxifylline—systemic scleroderma	0.000619	0.00303	CcSEcCtD
Enzalutamide—Paraesthesia—Captopril—systemic scleroderma	0.000616	0.00301	CcSEcCtD
Enzalutamide—Rhinitis—Mycophenolate mofetil—systemic scleroderma	0.000601	0.00294	CcSEcCtD
Enzalutamide—Mental disorder—Lisinopril—systemic scleroderma	0.000599	0.00293	CcSEcCtD
Enzalutamide—Dizziness—Pentoxifylline—systemic scleroderma	0.000598	0.00293	CcSEcCtD
Enzalutamide—Hypertension—Leflunomide—systemic scleroderma	0.000598	0.00293	CcSEcCtD
Enzalutamide—Hypoaesthesia—Mycophenolate mofetil—systemic scleroderma	0.000596	0.00292	CcSEcCtD
Enzalutamide—Infection—Azathioprine—systemic scleroderma	0.000595	0.00291	CcSEcCtD
Enzalutamide—Pharyngitis—Mycophenolate mofetil—systemic scleroderma	0.000595	0.00291	CcSEcCtD
Enzalutamide—Vertigo—Mycophenolic acid—systemic scleroderma	0.000594	0.00291	CcSEcCtD
Enzalutamide—Urinary tract disorder—Mycophenolate mofetil—systemic scleroderma	0.000592	0.00289	CcSEcCtD
Enzalutamide—Leukopenia—Mycophenolic acid—systemic scleroderma	0.000591	0.00289	CcSEcCtD
Enzalutamide—Fatigue—Captopril—systemic scleroderma	0.000591	0.00289	CcSEcCtD
Enzalutamide—Oedema peripheral—Mycophenolate mofetil—systemic scleroderma	0.00059	0.00289	CcSEcCtD
Enzalutamide—Arthralgia—Leflunomide—systemic scleroderma	0.00059	0.00289	CcSEcCtD
Enzalutamide—Connective tissue disorder—Mycophenolate mofetil—systemic scleroderma	0.000589	0.00288	CcSEcCtD
Enzalutamide—Anxiety—Leflunomide—systemic scleroderma	0.000588	0.00288	CcSEcCtD
Enzalutamide—Urethral disorder—Mycophenolate mofetil—systemic scleroderma	0.000587	0.00287	CcSEcCtD
Enzalutamide—Sepsis—Methotrexate—systemic scleroderma	0.000586	0.00287	CcSEcCtD
Enzalutamide—Thrombocytopenia—Azathioprine—systemic scleroderma	0.000586	0.00287	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Leflunomide—systemic scleroderma	0.000586	0.00287	CcSEcCtD
Enzalutamide—Skin disorder—Azathioprine—systemic scleroderma	0.000581	0.00285	CcSEcCtD
Enzalutamide—Back pain—Lisinopril—systemic scleroderma	0.000576	0.00282	CcSEcCtD
Enzalutamide—Convulsion—Mycophenolic acid—systemic scleroderma	0.000573	0.0028	CcSEcCtD
Enzalutamide—Hypertension—Mycophenolic acid—systemic scleroderma	0.00057	0.00279	CcSEcCtD
Enzalutamide—Headache—Pentoxifylline—systemic scleroderma	0.000567	0.00277	CcSEcCtD
Enzalutamide—Arthralgia—Mycophenolic acid—systemic scleroderma	0.000563	0.00275	CcSEcCtD
Enzalutamide—Infection—Leflunomide—systemic scleroderma	0.000562	0.00275	CcSEcCtD
Enzalutamide—Anxiety—Mycophenolic acid—systemic scleroderma	0.000561	0.00274	CcSEcCtD
Enzalutamide—Asthenia—Mometasone—systemic scleroderma	0.00056	0.00274	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.000559	0.00273	CcSEcCtD
Enzalutamide—Nervous system disorder—Leflunomide—systemic scleroderma	0.000554	0.00271	CcSEcCtD
Enzalutamide—Thrombocytopenia—Leflunomide—systemic scleroderma	0.000553	0.00271	CcSEcCtD
Enzalutamide—Pruritus—Mometasone—systemic scleroderma	0.000552	0.0027	CcSEcCtD
Enzalutamide—Skin disorder—Leflunomide—systemic scleroderma	0.000549	0.00269	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Azathioprine—systemic scleroderma	0.000545	0.00267	CcSEcCtD
Enzalutamide—Angiopathy—Mycophenolate mofetil—systemic scleroderma	0.000543	0.00266	CcSEcCtD
Enzalutamide—Dry skin—Prednisone—systemic scleroderma	0.000538	0.00263	CcSEcCtD
Enzalutamide—Infection—Mycophenolic acid—systemic scleroderma	0.000536	0.00262	CcSEcCtD
Enzalutamide—Vertigo—Lisinopril—systemic scleroderma	0.000535	0.00262	CcSEcCtD
Enzalutamide—Diarrhoea—Mometasone—systemic scleroderma	0.000534	0.00261	CcSEcCtD
Enzalutamide—Leukopenia—Lisinopril—systemic scleroderma	0.000533	0.00261	CcSEcCtD
Enzalutamide—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.000529	0.00259	CcSEcCtD
Enzalutamide—Thrombocytopenia—Mycophenolic acid—systemic scleroderma	0.000528	0.00258	CcSEcCtD
Enzalutamide—Mental disorder—Mycophenolate mofetil—systemic scleroderma	0.000525	0.00257	CcSEcCtD
Enzalutamide—Skin disorder—Mycophenolic acid—systemic scleroderma	0.000524	0.00256	CcSEcCtD
Enzalutamide—Muscular weakness—Prednisone—systemic scleroderma	0.000518	0.00253	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000517	0.00253	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.000515	0.00252	CcSEcCtD
Enzalutamide—Insomnia—Leflunomide—systemic scleroderma	0.000511	0.0025	CcSEcCtD
Enzalutamide—Paraesthesia—Leflunomide—systemic scleroderma	0.000508	0.00248	CcSEcCtD
Enzalutamide—Arthralgia—Lisinopril—systemic scleroderma	0.000507	0.00248	CcSEcCtD
Enzalutamide—Anxiety—Lisinopril—systemic scleroderma	0.000505	0.00247	CcSEcCtD
Enzalutamide—Back pain—Mycophenolate mofetil—systemic scleroderma	0.000504	0.00247	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000503	0.00246	CcSEcCtD
Enzalutamide—Asthenia—Captopril—systemic scleroderma	0.000492	0.00241	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000491	0.0024	CcSEcCtD
Enzalutamide—Headache—Mometasone—systemic scleroderma	0.000489	0.00239	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000488	0.00239	CcSEcCtD
Enzalutamide—Insomnia—Mycophenolic acid—systemic scleroderma	0.000488	0.00239	CcSEcCtD
Enzalutamide—Fatigue—Leflunomide—systemic scleroderma	0.000487	0.00238	CcSEcCtD
Enzalutamide—Pruritus—Captopril—systemic scleroderma	0.000485	0.00237	CcSEcCtD
Enzalutamide—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.000484	0.00237	CcSEcCtD
Enzalutamide—Infection—Lisinopril—systemic scleroderma	0.000483	0.00236	CcSEcCtD
Enzalutamide—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000476	0.00233	CcSEcCtD
Enzalutamide—Neutropenia—Prednisone—systemic scleroderma	0.000474	0.00232	CcSEcCtD
Enzalutamide—Skin disorder—Lisinopril—systemic scleroderma	0.000472	0.00231	CcSEcCtD
Enzalutamide—Diarrhoea—Captopril—systemic scleroderma	0.000469	0.0023	CcSEcCtD
Enzalutamide—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.000469	0.00229	CcSEcCtD
Enzalutamide—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000467	0.00228	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000466	0.00228	CcSEcCtD
Enzalutamide—Fatigue—Mycophenolic acid—systemic scleroderma	0.000465	0.00228	CcSEcCtD
Enzalutamide—Dizziness—Captopril—systemic scleroderma	0.000454	0.00222	CcSEcCtD
Enzalutamide—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.000452	0.00221	CcSEcCtD
Enzalutamide—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.00045	0.0022	CcSEcCtD
Enzalutamide—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000444	0.00217	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000443	0.00217	CcSEcCtD
Enzalutamide—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000442	0.00216	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000441	0.00216	CcSEcCtD
Enzalutamide—Insomnia—Lisinopril—systemic scleroderma	0.000439	0.00215	CcSEcCtD
Enzalutamide—Paraesthesia—Lisinopril—systemic scleroderma	0.000436	0.00213	CcSEcCtD
Enzalutamide—Headache—Captopril—systemic scleroderma	0.00043	0.0021	CcSEcCtD
Enzalutamide—AR—connective tissue—systemic scleroderma	0.000427	0.0442	CbGeAlD
Enzalutamide—Infection—Mycophenolate mofetil—systemic scleroderma	0.000423	0.00207	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000419	0.00205	CcSEcCtD
Enzalutamide—Fatigue—Lisinopril—systemic scleroderma	0.000419	0.00205	CcSEcCtD
Enzalutamide—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000417	0.00204	CcSEcCtD
Enzalutamide—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000417	0.00204	CcSEcCtD
Enzalutamide—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000413	0.00202	CcSEcCtD
Enzalutamide—Diarrhoea—Azathioprine—systemic scleroderma	0.00041	0.002	CcSEcCtD
Enzalutamide—Asthenia—Leflunomide—systemic scleroderma	0.000406	0.00198	CcSEcCtD
Enzalutamide—Pruritus—Leflunomide—systemic scleroderma	0.0004	0.00196	CcSEcCtD
Enzalutamide—Connective tissue disorder—Prednisone—systemic scleroderma	0.000399	0.00195	CcSEcCtD
Enzalutamide—Neutropenia—Methotrexate—systemic scleroderma	0.000396	0.00194	CcSEcCtD
Enzalutamide—Dizziness—Azathioprine—systemic scleroderma	0.000396	0.00194	CcSEcCtD
Enzalutamide—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.000394	0.00193	CcSEcCtD
Enzalutamide—AR—smooth muscle tissue—systemic scleroderma	0.000391	0.0404	CbGeAlD
Enzalutamide—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000388	0.0019	CcSEcCtD
Enzalutamide—Asthenia—Mycophenolic acid—systemic scleroderma	0.000387	0.00189	CcSEcCtD
Enzalutamide—Diarrhoea—Leflunomide—systemic scleroderma	0.000387	0.00189	CcSEcCtD
Enzalutamide—AR—skin of body—systemic scleroderma	0.000386	0.0399	CbGeAlD
Enzalutamide—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000385	0.00188	CcSEcCtD
Enzalutamide—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000382	0.00187	CcSEcCtD
Enzalutamide—Pruritus—Mycophenolic acid—systemic scleroderma	0.000382	0.00187	CcSEcCtD
Enzalutamide—Pneumonia—Methotrexate—systemic scleroderma	0.00038	0.00186	CcSEcCtD
Enzalutamide—Infestation NOS—Methotrexate—systemic scleroderma	0.000378	0.00185	CcSEcCtD
Enzalutamide—Infestation—Methotrexate—systemic scleroderma	0.000378	0.00185	CcSEcCtD
Enzalutamide—Headache—Azathioprine—systemic scleroderma	0.000375	0.00184	CcSEcCtD
Enzalutamide—Dizziness—Leflunomide—systemic scleroderma	0.000374	0.00183	CcSEcCtD
Enzalutamide—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000369	0.00181	CcSEcCtD
Enzalutamide—Angiopathy—Prednisone—systemic scleroderma	0.000368	0.0018	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000367	0.0018	CcSEcCtD
Enzalutamide—Haematuria—Methotrexate—systemic scleroderma	0.00036	0.00176	CcSEcCtD
Enzalutamide—Dizziness—Mycophenolic acid—systemic scleroderma	0.000357	0.00175	CcSEcCtD
Enzalutamide—Epistaxis—Methotrexate—systemic scleroderma	0.000357	0.00174	CcSEcCtD
Enzalutamide—Mental disorder—Prednisone—systemic scleroderma	0.000356	0.00174	CcSEcCtD
Enzalutamide—Headache—Leflunomide—systemic scleroderma	0.000354	0.00173	CcSEcCtD
Enzalutamide—Asthenia—Lisinopril—systemic scleroderma	0.000349	0.00171	CcSEcCtD
Enzalutamide—Pruritus—Lisinopril—systemic scleroderma	0.000344	0.00168	CcSEcCtD
Enzalutamide—Headache—Mycophenolic acid—systemic scleroderma	0.000338	0.00165	CcSEcCtD
Enzalutamide—Pharyngitis—Methotrexate—systemic scleroderma	0.000337	0.00165	CcSEcCtD
Enzalutamide—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000335	0.00164	CcSEcCtD
Enzalutamide—Urethral disorder—Methotrexate—systemic scleroderma	0.000333	0.00163	CcSEcCtD
Enzalutamide—Diarrhoea—Lisinopril—systemic scleroderma	0.000332	0.00163	CcSEcCtD
Enzalutamide—ABCB1—blood vessel—systemic scleroderma	0.000323	0.0334	CbGeAlD
Enzalutamide—Dizziness—Lisinopril—systemic scleroderma	0.000321	0.00157	CcSEcCtD
Enzalutamide—Vertigo—Prednisone—systemic scleroderma	0.000318	0.00155	CcSEcCtD
Enzalutamide—AR—digestive system—systemic scleroderma	0.000308	0.0319	CbGeAlD
Enzalutamide—Angiopathy—Methotrexate—systemic scleroderma	0.000308	0.00151	CcSEcCtD
Enzalutamide—Convulsion—Prednisone—systemic scleroderma	0.000306	0.0015	CcSEcCtD
Enzalutamide—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000305	0.00149	CcSEcCtD
Enzalutamide—Hypertension—Prednisone—systemic scleroderma	0.000305	0.00149	CcSEcCtD
Enzalutamide—Headache—Lisinopril—systemic scleroderma	0.000304	0.00149	CcSEcCtD
Enzalutamide—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000301	0.00147	CcSEcCtD
Enzalutamide—Arthralgia—Prednisone—systemic scleroderma	0.000301	0.00147	CcSEcCtD
Enzalutamide—Anxiety—Prednisone—systemic scleroderma	0.0003	0.00147	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000299	0.00146	CcSEcCtD
Enzalutamide—Mental disorder—Methotrexate—systemic scleroderma	0.000297	0.00145	CcSEcCtD
Enzalutamide—AR—tendon—systemic scleroderma	0.000293	0.0304	CbGeAlD
Enzalutamide—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000291	0.00142	CcSEcCtD
Enzalutamide—Infection—Prednisone—systemic scleroderma	0.000287	0.0014	CcSEcCtD
Enzalutamide—Back pain—Methotrexate—systemic scleroderma	0.000286	0.0014	CcSEcCtD
Enzalutamide—CYP2C19—digestive system—systemic scleroderma	0.000286	0.0296	CbGeAlD
Enzalutamide—Nervous system disorder—Prednisone—systemic scleroderma	0.000283	0.00138	CcSEcCtD
Enzalutamide—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000281	0.00138	CcSEcCtD
Enzalutamide—Skin disorder—Prednisone—systemic scleroderma	0.00028	0.00137	CcSEcCtD
Enzalutamide—CYP2B6—skin of body—systemic scleroderma	0.00028	0.0289	CbGeAlD
Enzalutamide—Headache—Mycophenolate mofetil—systemic scleroderma	0.000267	0.0013	CcSEcCtD
Enzalutamide—Vertigo—Methotrexate—systemic scleroderma	0.000265	0.0013	CcSEcCtD
Enzalutamide—Leukopenia—Methotrexate—systemic scleroderma	0.000264	0.00129	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000263	0.00129	CcSEcCtD
Enzalutamide—Insomnia—Prednisone—systemic scleroderma	0.000261	0.00128	CcSEcCtD
Enzalutamide—Paraesthesia—Prednisone—systemic scleroderma	0.000259	0.00127	CcSEcCtD
Enzalutamide—AR—lung—systemic scleroderma	0.000258	0.0266	CbGeAlD
Enzalutamide—Convulsion—Methotrexate—systemic scleroderma	0.000256	0.00125	CcSEcCtD
Enzalutamide—Arthralgia—Methotrexate—systemic scleroderma	0.000252	0.00123	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.00025	0.00122	CcSEcCtD
Enzalutamide—Fatigue—Prednisone—systemic scleroderma	0.000249	0.00122	CcSEcCtD
Enzalutamide—Infection—Methotrexate—systemic scleroderma	0.00024	0.00117	CcSEcCtD
Enzalutamide—Nervous system disorder—Methotrexate—systemic scleroderma	0.000236	0.00116	CcSEcCtD
Enzalutamide—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000236	0.00116	CcSEcCtD
Enzalutamide—Skin disorder—Methotrexate—systemic scleroderma	0.000234	0.00115	CcSEcCtD
Enzalutamide—CYP3A5—digestive system—systemic scleroderma	0.000225	0.0233	CbGeAlD
Enzalutamide—CYP2B6—digestive system—systemic scleroderma	0.000224	0.0231	CbGeAlD
Enzalutamide—CYP2C9—digestive system—systemic scleroderma	0.000222	0.0229	CbGeAlD
Enzalutamide—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.00022	0.00107	CcSEcCtD
Enzalutamide—Insomnia—Methotrexate—systemic scleroderma	0.000218	0.00107	CcSEcCtD
Enzalutamide—Paraesthesia—Methotrexate—systemic scleroderma	0.000216	0.00106	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000208	0.00102	CcSEcCtD
Enzalutamide—Fatigue—Methotrexate—systemic scleroderma	0.000208	0.00102	CcSEcCtD
Enzalutamide—Asthenia—Prednisone—systemic scleroderma	0.000207	0.00101	CcSEcCtD
Enzalutamide—Pruritus—Prednisone—systemic scleroderma	0.000204	0.000999	CcSEcCtD
Enzalutamide—Diarrhoea—Prednisone—systemic scleroderma	0.000197	0.000966	CcSEcCtD
Enzalutamide—Dizziness—Prednisone—systemic scleroderma	0.000191	0.000934	CcSEcCtD
Enzalutamide—CYP3A5—lung—systemic scleroderma	0.000188	0.0194	CbGeAlD
Enzalutamide—CYP2B6—lung—systemic scleroderma	0.000187	0.0193	CbGeAlD
Enzalutamide—Headache—Prednisone—systemic scleroderma	0.000181	0.000884	CcSEcCtD
Enzalutamide—Asthenia—Methotrexate—systemic scleroderma	0.000173	0.000846	CcSEcCtD
Enzalutamide—Pruritus—Methotrexate—systemic scleroderma	0.000171	0.000835	CcSEcCtD
Enzalutamide—CYP3A4—digestive system—systemic scleroderma	0.000169	0.0175	CbGeAlD
Enzalutamide—CYP2D6—digestive system—systemic scleroderma	0.000166	0.0172	CbGeAlD
Enzalutamide—Diarrhoea—Methotrexate—systemic scleroderma	0.000165	0.000807	CcSEcCtD
Enzalutamide—Dizziness—Methotrexate—systemic scleroderma	0.000159	0.00078	CcSEcCtD
Enzalutamide—Headache—Methotrexate—systemic scleroderma	0.000151	0.000739	CcSEcCtD
Enzalutamide—ABCB1—digestive system—systemic scleroderma	0.00012	0.0124	CbGeAlD
Enzalutamide—ABCB1—lung—systemic scleroderma	9.99e-05	0.0103	CbGeAlD
